Prescribe Right
Prescribe Right
  • Home
  • About
    • Endorsements
    • Published Articles
    • Consulting
    • Effective Pharmacotherapy
  • Pipeline News
    • Podcast
    • Recent Tweets
  • Pharmaceutical Pipeline Tracker
    • Access Pharmaceutical Pipeline Tracker
    • Pharmaceutical Pipeline Tracker Demo
    • Sample Drug Review
    • Case Studies >
      • Monitoring Drugs With PDUFA Dates
      • Monitoring Drugs By Therapeutic Category
      • Monitoring by Indication
      • Research a Single Drug
    • Sample Searches >
      • Single Drug Report Sample
      • Indication Search Sample
      • Drug Class Search Sample
      • Therapeutic Area Search Sample
      • Company Search Sample
  • Contact Us
  • Home
  • About
    • Endorsements
    • Published Articles
    • Consulting
    • Effective Pharmacotherapy
  • Pipeline News
    • Podcast
    • Recent Tweets
  • Pharmaceutical Pipeline Tracker
    • Access Pharmaceutical Pipeline Tracker
    • Pharmaceutical Pipeline Tracker Demo
    • Sample Drug Review
    • Case Studies >
      • Monitoring Drugs With PDUFA Dates
      • Monitoring Drugs By Therapeutic Category
      • Monitoring by Indication
      • Research a Single Drug
    • Sample Searches >
      • Single Drug Report Sample
      • Indication Search Sample
      • Drug Class Search Sample
      • Therapeutic Area Search Sample
      • Company Search Sample
  • Contact Us
Pipeline News and Updates
Picture

Update for December 22, 2020

12/21/2020

 
Regulatory Update
 
The FDA approved tirbanibulin (Klisyri, Athenex), on 12/15/2020, for the treatment of actinic keratosis on the face or scalp. 
 
The FDA approved margetuximab (Margenza, MacroGenics), on 12/17/2020, to be given in combination with chemotherapy, for the treatment of metastatic HER2-positive breast cancer in patients who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease. The drug was approved with a Boxed Warning regarding the potential for left ventricular dysfunction and embryo-fetal toxicity. MacroGenics anticipates availability of margetuximab in March of 2021.
 
The FDA approved relugolix (Orgovyx, Myovant Sciences) on 12/18/2020, for the treatment of advanced prostate cancer.
 
The FDA has delayed approval of Novartis’ inclisiran because travel restrictions have delayed the inspection of the manufacturing plant. A new PDUFA date has not been announced.
 
Amgen submitted a BLA for sotorasib for the treatment of metastatic non-small cell lung cancer with a KRAS G12C mutation.
 
Gilead and Galapagos are discontinuing development of filgotinib for the treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and non-infectious uveitis in the U.S. Gilead will continue to develop filgotinib for the treatment of Crohn’s Disease, while Galapagos will develop the drug for ulcerative colitis. Gilead returned co-marketing and development rights for filgotinib in Europe to Galapagos. The changes were made due to concerns by the FDA on testicular toxicity with the highest dose of filgotinib.
 
The FDA placed a clinical hold on UniQure’s etranacogene dezaparvovec clinical trials after a preliminary diagnosis of hepatocellular carcinoma was made in one patient enrolled in the Phase III HOPE-B trial.
 
The EMA has granted Orphan status to Acceleron Pharma’s sotatercept for the treatment of patients with pulmonary arterial hypertension.
 
Announced Research Updates
 
Roche announced that in the 255 patient arm of the Phase II, IPATunity130 trial, treatment with ipatasertib added to paclitaxel did not improve progression free survival compared to paclitaxel alone (7.4 vs 6.1 months) in patients with locally advanced or metastatic triple-negative breast cancer with alterations to the PIK3CA, AKT1 and PTEN genes.
 
VTV announced that in the 6-month, 43 patient, Phase II, ELEVAGE trial, azeliragon did not improve cognition (ADAS-cog14) compared to placebo in patients with mild probable Alzheimer’s Disease.
 
AB Science announced that in a 24-week, 718 patient, Phase IIb/III trial, treatment with masitinib improved the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) compared to placebo in patients with mild to moderate Alzheimer’s disease who were receiving a cholinesterase inhibitor (donepezil, rivastigmine or galantamine) and/or memantine.
 
Daiichi Sankyo announced that in a 14-week, 274 patient, Phase III trial, treatment with mirogabalin reduced pain more than placebo in patients with central neuropathic pain after spinal cord injury.
 
Roche announced that in two 1-year, Phase III trials, which included the 951 patient RHINE Trial and the 940 patient YOSEMITE trial, the change in best-corrected visual acuity from treatment with faricimab, at dosing intervals from eight to 16-weeks, was non-inferior to aflibercept given every eight weeks in patients with diabetic macular edema.
 
Published Research Updates
 
In the 150 patient Phase II, ProCAID trial, adding capivasertib to docetaxel plus prednisone did not improve progression free survival in patients with metastatic castration-resistant prostate cancer.
 
In a 12-week, 156 patient, Phase II trial, treatment with praliciguat did not improve the urine albumin to creatinine ratio compared to placebo in patients with type 2 diabetes and diabetic nephropathy.
 
Daiichi Sankyo announced that in a 14-week, 274 patient, Phase III trial, treatment with mirogabalin reduced pain more than placebo in patients with central neuropathic pain after spinal cord injury.

Update for December 15, 2020

12/14/2020

 
Regulatory Update
 
The FDA notified BMS of problems with sterilization procedures at the Washington plant that will manufacturer lisocabtagene maraleucel.
 
The FDA accepted the NDA for Scynexis's ibrexafungerp for the treatment of vulvovaginal candidiasis and set a PDUFA date for 6/1/2021.
 
The FDA accepted the NDA for Chimerix’s brincidofovir for the treatment of smallpox and set a PDUFA date for 4/7/2021.
 
The FDA accepted the NDA for reltecimod for the treatment of suspected organ dysfunction or failure in patients 12 years or older with necrotizing soft tissue infection, in conjunction with surgical debridement, antibiotic therapy, and supportive care. A PDUFA date has been set for 9/30/2021.
 
The FDA granted a Fast Track Designation to Immunicum’s Ilixadencel for the treatment of Gastrointestinal Stromal Tumors (GIST).
 
The FDA designated Amgen’s sotorasib a Breakthrough Therapy, for the treatment of locally advanced or metastatic non-small cell lung cancer with KRAS G12C mutation.
 
The FDA granted mavorixa a Fast Track designation for the treatment of WHIM syndrome.
 
The EMA has approved inclisiran for the treatment of hypercholesterolemia and mixed dyslipidemia.
 
Sanofi resumed fitusiran clinical trials in December 2020 with an adjusted dosing regimen designed to reduce adverse effects.
 
Announced Research Updates
 
ADC announced interim results from 18 patients enrolled in the Phase I/II, open-label, LOTIS 3 trial, where treatment with loncastuximab tesirine plus ibrutinib resulted in an ORR of 58.6% in patients with relapsed or refractory DLBCL and 83.3% in patients with mantle cell lymphoma (MCL). Patients with non-germinal center B-cell DLBCL had an ORR of 66.7% compared to 20% in germinal center B-cell DLBCL patients.
 
Oncopeptides announced interim data from 46 patients enrolled in the Phase II, open-label, ANCHOR trial, where patients treated with melflufen and dexamethasone plus daratumumab achieved an ORR of 73%, while patents treated with melflufen and dexamethasone plus bortezomib achieved a 62% ORR in patients with relapsed refractory multiple myeloma.
 
Gilead announced interim results from 64 patients enrolled in a Phase I, open-label trial, where treatment with magrolimab plus azacitidine resulted in a 63% objective response rate (ORR) in patients with myelodysplastic syndrome and a 63% ORR in patients with acute myeloid leukemia, who are ineligible for induction chemotherapy.
 
Lilly announced that in the 40-week, 478 patient, Phase III, SURPASS-1 trial, treatment with tirzepatide lowered HbA1c 1.87% with 5 mg, 1.89% with 10 mg and 2.07% with 15 mg compared to a 0.04% increase with placebo in patients with type 2 diabetes. Treatment with tirzepatide also lead to weight loss of 7 kg with 5 mg,7.8 kg with 10 mg and 9.5 kg with 15 mg compared to a 0.7 Kg loss with placebo. 
 
Biosight announced interim data from 31 patients enrolled in a Phase IIb trial, where treatment with aspacytarabine resulted in a 32% complete response rate in patients with acute myeloid leukemia who are not eligible for standard induction chemotherapy due to advanced age or comorbidities.
 
AlloVir announced that in the six-week, Phase II, CHARMS trial, patients treated with ALVR105 achieved a 93% clinical response (defined as complete response - viral load returning to normal range and resolution of clinical signs/symptoms or a partial response (50% or > decrease in viral load and/or 50% improvement of clinical signs/symptoms) in allo-hematopoietic stem cell transplantation patients with at least one treatment-refractory infection.
 
Roche announced interim results from 62 patients enrolled in a Phase I/Ib, open-label trial, where treatment with mosunetuzumab induced a complete response in 32/62 patients with relapsed or refractory follicular lymphoma.
 
Inovio announced that in a 6-month, 22 patient, Phase II trial, treatment with VGX-3100 resulted in resolution of HPV-16/18-associated precancerous anal lesions in 11/22 patients with high grade anal squamous intraepithelial lesions caused by HPV-16/18.
 
TG Therapeutics announced that in two 96-week Phase III trials involving 1,094 patients treatment with an intravenous infusion of ublituximab every six months resulted in a 60% annualized relapse rate (ARR) in ULTIMATE I and a 50% ARR in ULTIMATE II compared to daily oral teriflunomide in patients with relapsing forms of multiple sclerosis.
 
Apellis announced that in a 36-week, 77 patient, open-label extension of the Phase III PEGASUS trial, patients that continued pegcetacoplan maintained a hemoglobin increase of 2.7 g/dL and patients switched from eculizumab experienced a similar increase.
 
Published Research Updates
 
In a 24-week, 42 Japanese patient, Phase III, open label trial, treatment with vadadustat resulted in a mean Hb of 11.35 g/dL in patients with peritoneal dialysis-dependent CKD. 
 
In a 130-week, 69 peanut-allergy patient, Phase II trial, patients received 52-weeks of Viaskin Peanut 100 mcg, 250 mcg or placebo. After 52-weeks, all patients were switched to 250 mcg of Viaskin Peanut. At 130 weeks, desensitization was achieved in 1/20 placebo-250 mcg patients, 5/24 100 mcg-250 mcg patients and 9/25 participants who received 250 mcg for the full treatment duration.
 
In the 48-week, 1,045 patient, Phase III ATLAS-2M trial, 2% of patients that received IM injection of cabotegravir and rilpivirine every two months had an HIV-1 RNA of 50 copies/mL or > compared to 1% of patients that received the combination monthly, achieving non-inferiority for less frequent dosing.
 
In the 96-week, 37 patient, Phase III, REVERSE trial, lenadogen nolparvovec improved visual acuity from vision nadir by 15 letters in the treated eye, which was a non-significant difference compared to a 13 letter improvement in the eye that received a sham injection in patients with visual loss from Leber hereditary optic neuropathy
 
In a 26-week, 191 patient, open-label extension of a Phase III trial, patients that continued ravulizumab had lactate dehydrogenase (LDH) levels increased by 8.8% and four patients experienced breakthrough hemolysis compared to an LDH increase of 5.8% and one case of breakthrough hemolysis in patients switched from eculizumab to ravulizumab.
 
In the 157 patient, Phase II, open-label, HORIZON trial, treatment with melflufen plus dexamethasone resulted in an overall response rate of 29% in patients with multiple myeloma.

Update for December 8, 2020

12/8/2020

 
Regulatory Update
 
The FDA approved berotralstat (Orladeyo, BioCryst Pharmaceuticals), on 12/3/2020, for prevention of attacks of hereditary angioedema (HAE) in adults and pediatric patients 12 years and older. BioCryst set WAC at $485,000 per year. Berotralstat is the first oral treatment approved for treatment of HAE.
 
The FDA accepted the NDA from Kadmon for belumosudil for the treatment of chronic graft-versus-host disease and set a PDUFA date for 5/30/2021.
 
The FDA accepted the NDA from BridgeBio Pharma for infigratinib to treat patients with cholangiocarcinoma, which suggests a PDUFA date in April or May 2021.
 
Iterum has submitted an NDA for oral sulopenem etzadroxil/probenecid for the treatment of uncomplicated urinary tract infections in patients with a quinolone non-susceptible pathogen.
 
TG Therapeutics initiated a rolling BLA submission for ublituximab plus umbralisib for the treatment of patients with chronic lymphocytic leukemia.
 
The FDA granted ilixadencel, a Fast Track Designation for the treatment of Gastrointestinal Stromal Tumors (GIST).
 
Agenus began a rolling BLA for balstilimab for the treatment of recurrent/metastatic cervical cancer in September 2020 and plans to complete the submission in the first half of 2021.
 
Announced Research Updates
 
Ovid announced that in the 12-week, 97 patient, Phase III NEPTUNE trial, gaboxadol did not improve the Clinical Global Impression-Improvement-Angelman syndrome (CGI-I-AS) score compared to placebo (0.7 points vs 0.8) in patients with Angelman syndrome.
 
Takeda announced that in the eight-week, 352 patient, Phase III, SOLSTICE trial, more patients treated with maribavir achieved confirmed CMV viremia clearance compared to investigator-assigned treatment (ganciclovir, valganciclovir, foscarnet, or cidofovir) in transplant patients with refractory/resistant CMV infection.
 
AB Science announced that in a 383 patient, Phase III trial, treatment with masitinib plus gemcitabine increased overall survival by 1.8 months compared to gemcitabine alone (13 vs 11.2 months) in patients with unresectable locally advanced or metastatic pancreatic cancer patients with pain at baseline or taking opioids.
 
J&J announced data after 12.4-months in the 97 patient, Phase Ib/II CARTITUDE-1 trial, where ciltacabtagene autoleucel demonstrated an overall response rate of 97% and complete response of 67% in patients with relapsed multiple myeloma.
 
Published Research Updates
 
Interim data from 96 patients enrolled in the 48-week, 420 patient, Phase III, TALENT trial, found that 80.4% of patients treated with weekly albuvirtide plus ritonavir-boosted lopinavir achieved a plasma viral load below 50 copies/mL compared to 66% of patients who received daily lopinavir-ritonavir, tenofovir and lamivudine alone in adults who  failed their first antiretroviral regimen and have HIV-1 RNA levels >= 1000 copies/mL.
 
In a 51 patient, Phase II, open-label trial, treatment with umbralisib resulted in progression-free survival of 23.5 months in chronic lymphocytic leukemia patients who are intolerant to prior BTK inhibitors or prior PI3K delta inhibitors.
 
In a 164 patient, Phase II trial, indoximod added to paclitaxel or docetaxel did not improve progression-free survival compared to taxanes alone in patients with ERBB2-negative metastatic breast cancer.
 
In the 40-month, 91 patient, Phase IIb, VITAL trial, treatment with gemogenovatucel-T resulted in recurrence-free survival of 11.5 months compared to 8.4 months with placebo in patients with stage III/IV high-grade serous, endometrioid, or clear cell ovarian cancer.
 
AstraZeneca announced that in the 805 patient, Phase III, open-label, CASPIAN trial, the addition of tremelimumab to durvalumab plus platinum–etoposide did not improve overall survival compared to durvalumab plus platinum–etoposide (10.4 vs 10.5 months), however, durvalumab plus platinum–etoposide did increase overall survival compared to platinum–etoposide (12.9 vs 10.5 months), in patients with extensive-stage small cell lung cancer.
 
In a 12-week, 61 patient, Phase II trial, median ESA usage decreased by 15,000, 15,000, and 33,000 IU/week with 2, 6, and 20 mg doses of ziltivekimab in patients on hemodialysis with inflammation and hyporesponsiveness to ESA therapy.
 
In a 24-week, 299 patient, Phase II trial, imeglimin lowered HbA1c compared to placebo by 0.52% with imeglimin 500 mg, 0.94% with 1000 mg and 1% with 1,500 mg in Japanese patients with type 2 diabetes.

What Happened to the Potential Blockbusters Headed for Approval in 2020?

12/3/2020

 
Back in February we identified eleven potential blockbusters on track for approval in 2020. At this point, five have been approved and six are in need of additional data from trials before the FDA will grant approval. The five approvals covered the following indications: migraine, relapsing multiple sclerosis (2 drugs), breast cancer, and spinal muscular atrophy. 
Read on to review the status of these eleven potential blockbusters:
  1. Rimegepant from Biohaven Pharma (Nurtec ODT) -The FDA approved rimegepant on 2/27/2020 for the acute treatment of migraine with or without aura in adults. Rimegepant will compete with the triptans, ubrogepant and lasmiditan from Lilly. The gepants (ubrogepant and rimegepant) and lasmiditan do not cause vasoconstriction and may be an alternative when patients do not tolerate triptans. ICER reviewed lasmiditan, ubrogepant and rimegepant and found the drugs to be comparable in efficacy, but not as efficacious as triptans. Lasmiditan was found to have higher rates of dizziness and discontinuation. ICER concluded that lasmiditan, ubrogepant and rimegepant would provide a benefit for patients with cardiovascular disease that have a contraindication to triptans, were not helped by triptans or do not tolerate them.
  2. Celgene’s ozanimod (Zeposia) - The FDA approved ozanimod on 3/25/2020 for the treatment of adults with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. The outbreak of the COVID-19 pandemic delayed the launch of Zeposia. As of June 1, 2020, Zeposia is now available for prescription.
  3. Immunomedics/Seattle Genetics’ sacituzumab govitecan (Trodelvy) - The FDA approved sacituzumab govitecan on 4/22/2020 to treat resistant metastatic triple-negative breast cancer. Trodelvy has a boxed warning about the potential risks for severe diarrhea and neutropenia.
  4. The FDA approved risdiplam (Evrysdi) from Genentech/Roche on 8/7/2020, for treatment of spinal muscular atrophy (SMA) in adults and children 2 months of age and older. Risdiplam will be available through Accredo Health Group, an Express Scripts specialty pharmacy for direct delivery to patients’ homes. Risdiplam will compete with nusinersen (Spinraza, Biogen), which was approved in 2016. Risdiplam has weight and age based dosing until a child weighs 44 pounds. For patients that weigh 44 pounds or more, the dose is standardized to 5 mg per day. At 5 mg per day, Genentech has priced risdiplam at $340,000 per year. For an infant weighing 15 pounds, the annual cost would be less than $100,000. Both risdiplam and nusinersen increase production of survival motor neuron (SMN) protein. However, nusinersen is administered by intrathecal injection under anesthesia, while risdiplam is an oral liquid. WAC for nusinersen is $750,000 during the first year and $375,000 for each subsequent year.  Onasemnogene abeparvovec (Zolgensma, Novartis) is a single-dose gene therapy for SMA, but the drug has a price of over $2 million and a Black Box Warning regarding liver toxicity.
  5. Ofatumumab from Novartis (Kesimpta) - The FDA approved ofatumumab (Kesimpta, Novartis) on 8/21/2020, for the treatment of adults with relapsing multiple sclerosis. Ofatumumab is administered monthly via an autoinjector pen. Novartis has set WAC at $83,000 per year. Ofatumumab has the same mechanism of action as ocrelizumab (Ocrevus, Roche), which is administered by intravenous infusion every six months and has an annual WAC of $65,000. Ofatumumab (Arzerra, Novartis) was approved as an intravenous infusion in 2009 for the treatment of chronic lymphocytic leukemia.
  6. Vadadustat from Akebia Pharma/Mitsubishi Tanabe (no brand name available) – On 3 September 2020, Akebia Therapeutics announced top-line results from its PRO2TECT Global Phase 3 Program of Vadadustat for the treatment of Anemia due to chronic kidney disease in adult patients not on dialysis.
  7. AbbVie dropped a partnership to develop Filgotinib with Galapagos and Gilead who continued on with development for Crohn's disease, rheumatoid arthritis, Ankylosing spondylitis. Although the EU approved the drug, the FDA rejected filgotinib due to concerns over toxicity with the 200 mg dose. The FDA requested data from the ongoing MANTA and MANTA-RAY trials, which are not expected to be completed until 2021. This would potentially delay resubmission of the filgotinib NDA until mid-2021.
  8. Inclisiran, originally developed by a collaboration between Novartis, Alnylam Pharmaceuticals, and the Medicines Co., is in Phase III testing. The Medicines Company submitted an NDA for inclisiran to the FDA in December 2019. Novartis completed the purchase of The Medicines Company in January 2020. Inclusiran is administered as a subcutaneous injection. A second dose of inclusiran is administered 3 months after the first does as an initial loading dose regimen, then the drug is given every six months. Inclusiran lowers LDL by interfering with the RNA that leads to production of proprotein convertase subtilisin–kexin type 9 (PCSK9).
  9. Lisocabtagene maraleucel is in Phase II development by Bristol-Myers Squibb, Juno Therapeutics, and Celgene. The FDA accepted the NDA for lisocabtagene maraleucel for the treatment of large B-cell lymphoma and set a PDUFA date for August 2020. The PDUFA date was then delayed by three months in May 2020 to allow the FDA time to review new requested data. The FDA has delayed approval of lisocabtagene maraleucel due to travel restrictions delaying the inspection of the manufacturing plant. A new PDUFA date has not been announced.
  10. BioMarin Pharmaceutical’s valoctocogene roxaparvovec (Roctavian), to treat Hemophilia A, is in a Phase III trial expected to be concluded in November 2021, suggesting a 2021 resubmission of the valoctocogene roxaparvovec BLA. Previously, The FDA rejected valoctocogene roxaparvovec and said that at least two years of safety and efficacy data from the ongoing Phase III trial would be needed to support the sustainability of the reduced/eliminated Annualized Bleeding Rate. Three-year data from a Phase I/II trial suggested that factor VIII levels seemed to fall off after 12 to 18 months. This could potentially require additional doses to sustain efficacy, so the FDA would like additional data in a larger population.
  11. AstraZeneca has marketing rights for roxadustat in the U.S. and China, while Astellas holds the rights in Japan, Europe and the Middle East. The drug is in various Phase III trials. The FDA accepted the NDA for roxadustat for the treatment of both dialysis-dependent and non-dialysis dependent anemia and a set a PDUFA date of 12/20/2020.
    Stay informed, subscribe to the 
    ​
    Prescribe Right Pharmaceutical Pipeline Tracker
    Latest Tweets from Prescribe Right

    Archives

    March 2023
    February 2023
    January 2023
    December 2022
    October 2022
    September 2022
    August 2022
    July 2022
    June 2022
    May 2022
    April 2022
    March 2022
    February 2022
    January 2022
    December 2021
    November 2021
    October 2021
    September 2021
    August 2021
    July 2021
    June 2021
    May 2021
    April 2021
    March 2021
    February 2021
    January 2021
    December 2020
    November 2020
    October 2020
    September 2020
    August 2020
    July 2020
    June 2020
    May 2020
    April 2020
    March 2020
    February 2020
    January 2020
    December 2019
    November 2019
    October 2019
    September 2019
    August 2019
    July 2019
    June 2019
    May 2019
    April 2019
    March 2019
    February 2019
    January 2019
    December 2018
    November 2018
    October 2018
    September 2018
    August 2018
    June 2018
    May 2018
    April 2018
    March 2018
    February 2018
    January 2018
    December 2017
    November 2017
    October 2017
    September 2017
    August 2017
    August 2015

    RSS Feed

Services

Pharmaceutical Pipeline Tracker​
Consulting

Company

About
Blog
Tweets

Support

Contact
© COPYRIGHT 2015. ALL RIGHTS RESERVED.